

Executive summary

	<ul style="list-style-type: none"> » Premature and low birth weight infants are at greater risk of increased mortality and morbidity from vaccine preventable diseases. » Except for BCG, immunisations should be given according to the National Immunisation Schedule at the appropriate chronological age. <ul style="list-style-type: none"> » Do not adjust age for preterm birth, i.e. National Immunisation Schedule vaccines start at 6 weeks of age from the date of birth. » The usual vaccine dosage should be used.
Vaccine immunogenicity	» Inferior immune response to some vaccines although evidence suggests the response is still protective.
Vaccine safety	» Immunisation in these infants is safe and effective. However, post-immunisation apnoea with or without associated bradycardia up to 48 hours post-immunisation may be increased in some groups.
Apnoea	<ul style="list-style-type: none"> » Factors possibly associated with an increased incidence of post-immunisation apnoea: <ul style="list-style-type: none"> » Apnoea within the 24-hour period before immunisation. » More severe illness at birth. » Chronological age less than 67 days and/or earlier gestational age in infants with a birth weight of less than 1500g. » An apnoeic episode following the first immunisation event.
Apnoea monitoring	<ul style="list-style-type: none"> » Consider after the first immunisation event. » Consider after subsequent immunisation events when an infant has experienced apnoea after their first immunisation event. » No long-term sequelae have been associated with post immunisation apnoeic events. » Immunisation should not be withheld or delayed.
Vaccine administration	<ul style="list-style-type: none"> » Preferred site for intramuscular immunisation is the vastus lateralis. » A 23–25 gauge x 16mm needle inserted at a 90° angle to the skin is usually adequate.
Targeted immunisation or cocooning	<ul style="list-style-type: none"> » Immunisation of close contacts <ul style="list-style-type: none"> » Some close contacts may be eligible to receive a funded pertussis booster immunisation. Others can purchase the vaccine through their family doctor or some community pharmacies. » Influenza immunisation is not funded on the basis of being a close contact. The vaccine can be purchased through their family doctor or some community pharmacies.
Recommendations for individual vaccines	
Infants born to hepatitis B carrier mothers	<ul style="list-style-type: none"> » Give hepatitis B immunoglobulin (HBIG) and a hepatitis B immunisation (Engerix-B® 20mcg/mL) within 12 hours of birth regardless of birth weight, followed by: <ul style="list-style-type: none"> » Three doses of hepatitis B containing vaccine (DTaP-IPV-HepB/Hib [Infanrix®-hexa]) beginning at 6 weeks of age, regardless of birth weight. Serology testing for hepatitis B infection (HBsAg) and immunity (antiHBs) is recommended at 9 months of age.
Infants of non-hepatitis B carrier mothers	» Three doses of hepatitis B containing vaccine (DTaP-IPV-HepB/Hib [Infanrix-hexa]) beginning at 6 weeks of age, regardless of birth weight.
Tuberculosis (BCG)	<ul style="list-style-type: none"> » Eligible infants born at 34 weeks gestation or later can receive the BCG vaccine soon after birth. » Eligible infants born before 34 weeks gestation should have their BCG delayed until 34 weeks gestational age.
Diphtheria, tetanus, pertussis, polio and <i>Haemophilus influenzae</i> type b (Hib)	<ul style="list-style-type: none"> » Three doses beginning at 6 weeks of age. » Administer as DTaP-IPV-HepB/Hib (Infanrix-hexa).
Pneumococcal disease	<ul style="list-style-type: none"> » Infants who are <u>not</u> eligible for the high-risk pneumococcal immunisation programme <ul style="list-style-type: none"> » Give the routine National Immunisation Schedule pneumococcal conjugate vaccine (PCV10/Synflorix®) at 6 weeks, 5 months and 15 months of age. » Infants who are eligible for the high-risk pneumococcal immunisation programme <ul style="list-style-type: none"> » PCV13/Prevenar 13® at 6 weeks, 3 months, 5 months and 15 months of age replaces PCV10/Synflorix. » Two 23-valent pneumococcal polysaccharide vaccine doses (23PPV/Pneumovax®23) are recommended and funded if the infant continues to be at high-risk of pneumococcal disease, the first at 2 years of age and the second five years after the first.
Rotavirus	<ul style="list-style-type: none"> » Two doses of rotavirus vaccine (Rotarix®) beginning at 6 weeks of age. <ul style="list-style-type: none"> » Infants in hospital at 6 weeks of age should receive the first Rotarix dose on time. » No increase in nosocomial rotavirus transmission within neonatal intensive care units. » Standard infection control precautions should be maintained.
Influenza	<ul style="list-style-type: none"> » Influenza vaccine annually from 6 months of age. <ul style="list-style-type: none"> » Preterm birth alone does not meet the eligibility criteria for receipt of funded vaccine. » Two doses of vaccine administered one month apart in the first year, then one dose annually in each subsequent year.

Young infants are especially vulnerable to a number of vaccine preventable diseases, particularly pertussis (whooping cough), *Haemophilus influenzae* type b (Hib) disease, pneumococcal disease and influenza. Preterm and low birth weight infants have an even higher risk than full term infants of developing serious complications from vaccine preventable diseases.

Preterm birth is defined as birth before 37 weeks gestation and low birth weight refers to infants born weighing less than 2500 grams. Except for the BCG vaccine, gestational age and birth weight are not limiting factors when deciding whether a clinically stable preterm infant is to be immunised at the appropriate chronological age, following the same immunisation schedule as infants born full-term. The recommended dose of each vaccine should be used, doses should not be divided.

Passive immunity in preterm infants

Transplacental transfer of maternal immunoglobulin G (IgG) that can protect an infant against some vaccine preventable diseases is affected by a range of factors including the mother's past exposure to the disease and immunisation history, antibody half-life, and the infant's gestational age. Around 28–32 weeks gestation, the levels of maternal IgG in the infant are only around half of the maternal levels, compared with higher than maternal IgG levels in term infants. Furthermore, IgG wanes more rapidly rendering preterm infants at increased and earlier risk for vaccine preventable diseases.

Vaccine immunogenicity

Preterm infants have an inferior immune response to some vaccines although evidence suggests that the response is still adequate for protection.

Vaccine safety

Vaccines in preterm and/or low birth weight infants have excellent safety profiles, comparable to those in full term infants, except for a possible increase in apnoea with or without associated bradycardia up to 48 hours post-immunisation.

Apnoea

Factors that have been identified as possibly being associated with an increased incidence of post-immunisation apnoea include apnoea within the 24 hour period before immunisation, more severe illness at birth, chronological age less than 67 days, and/or earlier gestational age in infants with a birth weight of less than 1500g. Although apnoeic episodes are not necessarily causally associated with immunisation, an apnoeic episode following the first immunisation event is a significant risk factor for an apnoeic episode following the second immunisation event. No long-term sequelae have been associated with post immunisation apnoeic events.

Apnoea monitoring

Apnoea monitoring of preterm and/or low birth weight infants, particularly those with a history of respiratory immaturity, should be considered after the first immunisation event. When an infant has experienced apnoea after their first immunisation event, apnoea monitoring (for both medical reasons and to maintain parental confidence in immunisation) should be considered after subsequent immunisation events. Immunisation should not be withheld or delayed.

Vaccine administration

The preferred site for intramuscular immunisation in preterm or low birth weight infants is the same as for full term infants, the vastus lateralis. A 23–25 gauge x 16mm needle inserted at a 90° angle to the skin is usually adequate.

Targeted immunisation or cocooning

Research suggests that most infants acquire diseases such as whooping cough and influenza from family members. "Cocooning" or "targeted immunisation" involves ensuring siblings are up to date with their immunisations, and immunising the infant's close contacts (parents, grandparents and carers) to reduce the risk of disease exposure for the infant. Important vaccines to consider include pertussis-containing vaccines and influenza vaccines.

Estimates of pertussis vaccine efficacy in adolescents and adults vary from 51–92%. In those who develop immunity, protection against disease is highest over the first year after immunisation and wanes rapidly over 4–6 years. Reducing the risk of close contacts having active disease is beneficial for infants.

However, pertussis carriage and transmission of bacteria from asymptomatic contacts may be possible. Studies measuring the "cocoon" effect from targeted pertussis immunisation report 'no benefit' to around a 50% reduction in the pertussis disease risk in infants aged under 4 months.

Any adult with a cough needs to have pertussis excluded before spending time with infants even if they have received a pertussis booster immunisation. Despite a relatively rapid loss of protection in vaccine responders, booster doses of pertussis-containing vaccine are recommended no more frequently than 10-yearly for non-pregnant adolescents and adults.

One pertussis booster vaccination (Tdap/Boostrix) dose is free for parents or primary caregivers of an infant admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than three days and whose mother did not receive maternal Tdap vaccination at least 14 days before birth.

For infants born before 32 weeks gestation and whose mother received maternal Tdap vaccination more than 14 days before birth, one pertussis booster vaccination is also recommended, but not funded, for parents or primary caregivers as the level of transplacental maternal antibodies in these infants is only around half of the maternal circulating antibody level.

Influenza vaccine efficacy is dependent on the age, immune status and health of the recipient, as well as the match between the vaccine influenza strains and strains circulating in the community. Influenza vaccines are not funded by the Ministry of Health on the basis of a person being a close contact but can be purchased through the person's general practice or some community pharmacies. Influenza vaccination for healthcare workers is usually funded by their employer.

Recommendations for individual vaccines

Hepatitis B

Infants born to hepatitis B carrier mothers

Infants born to HBsAg-positive (hepatitis B surface antigen-positive) mothers require hepatitis B immunoglobulin (HBIG) and a hepatitis B immunisation within 12 hours of birth.

Without hepatitis B immunoprophylaxis these infants have up to a 50% risk of acquiring the disease perinatally and more than 90% likelihood of progressing to chronic hepatitis if they do acquire the disease with the associated lifelong risk of developing liver cirrhosis and cancer.

When the mother is also HBeAg-positive (a marker for high viral replication) at the time of delivery, the risk of perinatal hepatitis B infection increases to 90%. However, routine testing for HBeAg is not done because infection can still be transmitted when the HBeAg is non-detectable.

Continued...

Infants born to hepatitis B carrier mothers continued
HBIG is expected to be effective in very low birth weight infants. In a small study 10 infants, all weighing less than 1750g when born to hepatitis B carrier mothers, received HBIG at birth but no hepatitis B immunisation until 11–59 days old. No infants became hepatitis B surface antigen positive.

Some studies suggest that infants weighing less than 2000g at birth have decreased seroconversion to hepatitis B vaccine. Corticosteroid use and hyperbilirubinaemia may also reduce the immune response to hepatitis B vaccine. However, these are not reasons to delay the birth hepatitis B immunisation. By 4 weeks of age all infants, independent of gestational age and birth weight, are expected to respond to the hepatitis B vaccine and develop protection against the disease.

In New Zealand, a complete course of three hepatitis B vaccine doses are administered from 6 weeks of age irrespective of whether the infant had a birth dose of vaccine. Serology testing for hepatitis B infection (HBsAg) and immunity (antiHBs) is recommended at 9 months of age for all infants born to hepatitis B carrier mothers.

Infants born to mothers whose hepatitis B carrier status is not known

Infants of mothers whose HBsAg status is unknown at the time of delivery require hepatitis B immunisation at birth while waiting for the results of urgent HBsAg testing on the mother. If mother is found to be HBsAg positive, HBIG will also be required regardless of their birth weight.

Infants of non-hepatitis B carrier mothers

Infants born to hepatitis B negative (HBsAg negative) mothers prematurely and/or weighing less than 2000g are expected to be adequately protected against hepatitis B after three doses of vaccine beginning at 6 weeks of age.

BCG

It is recommended that the BCG immunisation is administered soon after birth to infants who are at increased risk of tuberculosis and meet the eligibility criteria described in table 1 on the following page.

Studies measuring the preterm and/or low birth weight infant's response to the BCG immunisation have used BCG scar, Mantoux response and/or the lymphocyte migration inhibition test to assess the infant's response. Some data indicates that administering the BCG immunisation at a gestational age of 34 weeks or later provides a good immune response. Other data suggests that the BCG immunisation can be given as early as a gestational age of 31 weeks. As these methods are now known to provide false negative indicators of immune response, and in the absence of recent data using modern and more accurate tests, a conservative approach to administering the BCG to preterm and/or low birth weight infants is advised.

Infants born at 34 weeks gestation or later can receive the vaccine soon after birth. Infants born before 34 weeks gestation should have their BCG delayed until they reach a gestational age of 34 weeks.

Diphtheria, tetanus, pertussis, polio and *Haemophilus influenzae* type b (Hib)

Diphtheria and tetanus toxoid vaccines are highly immunogenic in preterm infants. The immune response to the acellular pertussis vaccine in preterm infants has been shown to be lower than in those born at full term but has been shown to be efficacious when administered to preterm infants.

Pneumococcal

Both the 10-valent (PCV10/Synflorix) and 13-valent pneumococcal conjugate (PCV13/Prevenar 13) vaccines have been shown to be immunogenic in infants born before 37 weeks gestation and infants born at less than 2500g but earlier gestational age and/or extremely low birth weight may influence the magnitude of antibody response and duration of protection following the primary vaccine course.

Timely administration of the booster dose in the second year of life is recommended. PCV10 and PCV13 have also been shown to be safe and generally well tolerated in preterm and/or low birth weight infants.

Eligibility for the high-risk pneumococcal immunisation programme for infants and children aged under 5 years is outlined in table 2 on the following page.

Infants who are not eligible for the high-risk pneumococcal immunisation programme are recommended to receive the routine National Immunisation Schedule pneumococcal conjugate vaccine (PCV10/Synflorix) at ages 6 weeks, 5 months and 15 months.

Infants who are eligible for the high-risk of pneumococcal immunisation programme are recommended to receive PCV13/Prevenar 13 at ages 6 weeks, 3 months, 5 months and 15 months instead of PCV10/Synflorix. Two 23-valent pneumococcal polysaccharide vaccine doses (23PPV/Pneumovax23) are recommended and funded if the infant continues to be at high-risk of pneumococcal disease, the first at 2 years of age and the second five years after the first.

Rotavirus

Rotarix has been shown to be safe and efficacious when given to preterm infants born between 27–36 weeks gestation following the same schedule as full-term infants. Adverse events and vaccine immunogenicity were comparable with the preterm cohort receiving the placebo and term infants in an earlier Rotarix safety and immunogenicity study.

The weakened (attenuated) rotavirus from Rotarix may be found in stools for up to 28 days after the first immunisation and up to 15 days after the second. However, no increase in nosocomial rotavirus transmission within neonatal intensive care units has been observed. Standard infection control precautions should be maintained.

Preterm infants are at increased risk for hospitalisation from rotavirus during their early years of life. Rotarix can be administered to medically stable, hospitalised infants at 6 weeks of age. The vaccine has been shown to be well-tolerated in these infants, and no increase in nosocomial rotavirus transmission was observed within the neonatal intensive care unit (NICU).

Influenza

Annual influenza vaccine is recommended for all preterm infants from 6 months of age. However, preterm birth alone does not meet the eligibility criteria for receipt of funded vaccine. All infants and children aged under 9 years receiving influenza vaccine for the first time require two doses of vaccine administered one month apart, then one dose annually in each subsequent year.

Continued...

Table 1: Neonatal BCG eligibility criteria

Neonatal BCG is recommended and funded for infants at increased risk of TB, defined as those who:

- » will be living in a house or family/whānau with a person with either current TB or a history of TB
- » have one or both parents or household members or carers who within the last five years lived for a period of six months or longer in countries with a TB rate ≥ 40 per 100,000*
- » during their first five years will be living for three months or longer in a country with a TB rate ≥ 40 per 100,000.*

*A list of high-incidence countries and their TB rates is available in Appendix 8 in the *Immunisation Handbook*.

Table 2: Eligibility for the high-risk pneumococcal immunisation programme for infants and children aged under 5 years

<ul style="list-style-type: none"> » Cardiac disease with cyanosis or failure » Cerebrospinal fluid leak » Chronic pulmonary disease, including asthma treated with high-dose corticosteroid therapy » Cochlear implant » Corticosteroid therapy for more than two weeks and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater » Diabetes » Down syndrome » Functional asplenia 	<ul style="list-style-type: none"> » HIV-positive » Immunosuppressive therapy » Intracranial shunt » Nephrotic syndrome » Pre-or post-splenectomy » Pre-term infant born before 28 weeks gestation » Primary immune deficiency » Post-haematopoietic stem cell transplantation » Post-solid organ transplantation » Radiation therapy » Renal failure
--	--

References

- Baxter D. Impaired functioning of immune defenses to infection in premature and term infants and their implications for vaccination. *Hum Vaccin*. 2010;6(6):494-505.
- Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. *Am J Epidemiol*. 1977;105(2):94-8.
- Byrne L, Campbell H, Andrews N, Ribeiro S, Amirthalingam G. Hospitalisation of preterm infants with pertussis in the context of a maternal vaccination programme in England. *Arch Dis Child*. 2017;0:1-69.
- Carbone T, McEntire B, Kissin D, Kelly D, Steinschneider A, Violaris K, et al. Absence of an increase in cardiorespiratory events after diphtheria-tetanus-acellular pertussis immunization in preterm infants: A randomized, multicenter study. *Pediatrics*. 2008;121(5):e1085-90.
- Chiu M, Bao C, Sadarangani M. Dilemmas with rotavirus vaccine: The neonate and immunocompromised. *Pediatr Infect Dis J*. 2019;38(Supple 6):S43-6.
- Clifford V, Crawford NW, Royle J, Lazzaro T, Danchin M, Perrett KP, et al. Recurrent apnoea post immunisation: Informing re-immunisation policy. *Vaccine*. 2011;29(34):5681-7.
- Crawford NW, Buttery JP. Preterm infants immunization. *J Paediatr Child Health*. 2010;20(6):297-301.
- Crawford NW, Bines JE, Royle J, Buttery JP. Optimizing immunization in pediatric special risk groups. *Expert Rev Vaccines*. 2011;10(2):175-86.
- Davis AR, Rosenthal P. Hepatitis B in children. *Pediatr Rev*. 2008;29(4):111-20.
- D'Angio C. Active immunization of premature and low birth-weight infants: a review of immunogenicity, efficacy, and tolerability. *Pediatr Drugs*. 2007;9(1):17-32.
- D'Angio CT, Heyne RJ, O'Shea TM, Schelonka RL, Shankaran S, Duara S, et al. Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. *Pediatr Infect Dis J*. 2010;29(7):600-6.
- Eberhardt CS, Blanchard-Rohner G, Lemaître B, Boukrid M, Combescure C, Othenin-Girard V, et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. *Clin Infect Dis*. 2016;62(7):829-36.
- Eberhardt CS, Blanchard-Rohner G, Lemaître B, Combescure C, Othenin-Girard V, Chilin A, et al. Pertussis antibody transfer to preterm neonates after second- versus third-trimester maternal immunization. *Clin Infect Dis*. 2017;64(8):1129-32.
- Edwards KM, Decker MD. Pertussis vaccines. In: Plotkin S, Orenstein W, Offit P, editors. *Vaccines*. 7th ed. London: W.B. Saunders; 2017. p. 711-761.
- Esposito S, Pugni L, Bosis S, Proto A, Cesati L, Bianchi C, et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. *Vaccine*. 2005;23(14):1703-8.
- Esposito S, Serra D, Gualtieri L, Cesati L, Principi N. Vaccines and preterm neonates: Why, when, and with what. *Early Hum Dev*. 2009;85(10, Supplement):S43-5.
- Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. *Clin Vaccine Immunol*. 2010;17(6):1017-26.
- Esposito S, Pugni L, Mosca F, Principi N. Rotarix and RotaTeq administration to preterm infants in the neonatal intensive care unit: Review of available evidence. *Vaccine*. 2018;36(36):5430-4.
- Flatz-Jequier A, Posfay-Barbe KM, Pfister RE, Siegrist C-A. Recurrence of cardiorespiratory events following repeat DTaP-based combined immunization in very low birth weight premature infants. *J Pediatr*. 2008;153(3):429-31.
- Furck AK, Richter JW, Kattner E. Very low birth weight infants have only few adverse events after timely immunization. *J Perinatol*. 2010;30(2):118-21.

Continued...

References continued

- Gad A, Shah S. Special immunization considerations of the preterm infant. *J Pediatr Health Care*. 2007;21(6):385-91.
- Huang F, Lee P, Lee C, Huang L, Chang L, Liu S. Hepatitis B vaccination in preterm infants. *Arch Dis Child Fetal Neonatal Ed*. 1997;77(2):F135-8.
- Klein NP, Massolo ML, Greene J, Dekker CL, Black S, Escobar GJ, et al. Risk factors for developing apnea after immunization in the neonatal intensive care unit. *Pediatrics*. 2008;121(3):463-9.
- Kroger A, Atkinson W, Pickering L. General immunization practices. In: Plotkin S, Orenstein W, Offit P, editors. *Vaccines*. 7th ed. London: W.B. Saunders; 2017. p. 96-120.
- Lau Y-L, Tam A, Ng K, Tsoi N, Lam B, Lam P, et al. Response of preterm infants to hepatitis B vaccine. *J Pediatr*. 1992;121(6):962-5.
- Losonsky G, Wasserman S, Stephens I, Mahoney F, Armstrong P, Gumpfer K, et al. Hepatitis B vaccination of premature infants: A reassessment of current recommendations for delayed immunization. *Pediatrics*. 1999;103(2):e14.
- Martinon-Torres F, Czajka H, Center KJ, Wysocki J, Majda-Stanislawski E, Omenaca F, et al. 13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants. *Pediatr*. 2015;135(4):e876-886.
- Martinon-Torres F, Wysocki J, Center KJ, Czajka H, Majda-Stanislawski E, Omenaca F, et al. Circulating antibody 1 and 2 years after vaccination with the 13-valent pneumococcal conjugate vaccine in preterm compared with term infants. *Pediatr Infect Dis J*. 2017;36(3):326-332.
- Ministry of Health. *Immunisation handbook 2017 2nd Edition* [Internet]. Wellington: Ministry of Health; 2017. [updated March 2018; cited 2020 July 10]. Available from: <https://www.health.govt.nz/publication/immunisation-handbook-2017>.
- Omenaca F, Garcia-Sicilia J, Boceta R, Garcia-Corbeira P. Hepatitis B response of premature infants after primary and booster immunisation with a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus/Haemophilus influenzae type b vaccine. *Infect Dis Obstet Gynecol*. 2010;2010:1.
- Omenaca F, Merino JM, Tejedor J-C, Constantopoulos A, Papaevangelou V, Kafetzis D, et al. Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine. *Pediatr*. 2011;128(2):e290-298.
- Omenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, Smolenov IV, Han HH, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European infants. *Pediatr Infect Dis J*. 2012;31(5):487-493.
- Omenaca F, Vazquez L, Garcia-Corbeira P, Mesaros N, Hanssens L, Dolhain J, et al. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. *Vaccine*. 2018;36(7):986-96.
- Pfister RE, Aeschbach V, Niksic-Stubler V, Martin BC, Siegrist C-A. Safety of DTaP-based combined immunization in very-low-birth-weight premature infants: Frequent but mostly benign cardiorespiratory events. *J Pediatr*. 2004;145(1):58-66.
- Ruggeberg JU, Collins C, Clarke P, Johnson N, Sinha R, Everest N, et al. Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. *Vaccine*. 2007;25(2):264-71.
- Schloesser R, Fischer D, Otto W, Rettwitz-Volk W, Herden P, Zielen S. Safety and immunogenicity of an acellular pertussis vaccine in premature infants. *Pediatrics*. 1999;103(5):e60.
- Schulzke S, Heining U, Lucking-Famira M, Fahnenstich H. Apnoea and bradycardia in preterm infants following immunisation with pentavalent or hexavalent vaccines. *Eur J Pediatr*. 2005;164(7):432-5.
- Sedaghatian MR, Hashem F, Hossain MM. Bacille Calmette Guerin vaccination in pre-term infants. *Int J Tuberc Lung Dis*. 1998;2(8):679-82.
- Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: Epidemiology and vaccination. *Epidemiol Rev*. 2006;28(1):112-25.
- Shinefield HM, Black SM, Ray PM, Fireman BM, Schwalbe JM, Lewis EM. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. *Pediatr Infect Dis J*. 2002;21(3):182-6.
- Sicard M, Bryant K, Muller ML, Quach C. Rotavirus vaccination in the neonatal intensive care units: where are we? A rapid review of recent evidence. *Curr Opin Pediatr*. 2020;32(1):167-91.
- Szynczewska E, Chlebna-Soko D. Immunogenicity of heptavalent conjugate vaccine against *Streptococcus pneumoniae* in premature babies with low birth weight. *Vaccine*. 2014;55(2):101-7.
- Tan CX, Chan S-M, Lee I-Y, Ong C, Phua K-B, Aw MM, et al. Serologic responses after hepatitis B vaccination in preterm infants born to hepatitis B surface antigen-positive mothers. Singapore experience. *Pediatr Infect Dis J* 2017;36(8):e208-e210
- Thayyil-Sudhan S, Kumar A, Singh M, Paul VK, Deorari AK. Safety and effectiveness of BCG vaccination in preterm babies. *Arch Dis Child Fetal Neonatal Ed*. 1999;81(1):F64-6.
- van den Berg JP, Westerbeek EAM, van der Klis FRM, Berbers GAM, van Elburg RM. Transplacental transport of IgG antibodies to preterm infants: A review of the literature. *Early Hum Dev*. 2011;87(2):67-72.
- Vesikari T, Karvonen A, Prymula R, et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. *Vaccine*. 2010;28:5272-5279.
- Ygberg S, Nilsson A. The developing immune system - from foetus to toddler. *Acta Paediatr*. 2011;101(2):120-7.